Retrophin, Inc. (NASDAQ:RTRX) announced that it has signed a binding commitment on a $40 million senior secured term loan facility, provided by Athyrium Capital Management. The term loan will mature in 2018, have an interest rate of LIBOR plus 10% (with a LIBOR floor of 1%), and be subject to customary closing conditions. The lender will receive warrants to purchase an aggregate of 300,000 shares of common stock for a period of five years at an exercise price of $13.93 per share. Retrophin Inc (NASDAQ:RTRX) weekly performance is 10.26%. On last trading day company shares ended up $14.62. Analysts mean target price for the company is $39.00. Retrophin Inc (NASDAQ:RTRX) distance from 50-day simple moving average (SMA50) is -5.26%.
Zogenix, Inc. (NASDAQ:ZGNX) a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Stephen Farr, Ph.D., President, and Ann Rhoads, Chief Financial Officer, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City on June 4, 2014. Zogenix, Inc. (NASDAQ:ZGNX) shares advanced 5.99% in last trading session and ended the day on $2.30. Gross Margin is 39.20% and its return on assets is -127.10%. Zogenix, Inc. (NASDAQ:ZGNX) quarterly performance is -47.13%.
On May 28, TherapeuticsMD, Inc. (NYSEMKT:TXMD) a women’s healthcare company and parent company of vitaMedMD, LLC (“vitaMedMD”) and BocaGreenMD, Inc. (“BocaGreenMD”), announced the availability of the newly reformulated vitaMedMD®branded prescription prenatal vitamin, vitaMedMD RediChew™ Rx, and the BocaGreenMD® generic prescription prenatal vitamin Prena1 Chew.vitaMedMD RediChew Rx and Prena1 Chew are small, vanilla flavored, chewable prenatal vitamin tablets that dissolve quickly and are taken once daily. TherapeuticsMD Inc (NYSEMKT:TXMD) shares moved down -2.87% in last trading session and was closed at $4.06 , while trading in range of $3.88 – $4.25. TherapeuticsMD Inc (NYSEMKT:TXMD) year to date (YTD) performance is -22.07%.
On May 13, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced financial results and operational update for the first quarter ended March 31, 2014. Net loss for the first quarter ended March 31, 2014 was $7.9 million, compared to $7.6 million for the same period in 2013. Operating expenses for the three months ended March 31, 2014 increased to $7.6 million from $6.9 million in the same period of 2013 primarily due to an increase of $0.8 million in research and development expense. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) ended the last trading day at $3.09. Company weekly volatility is calculated as 4.22% and price to cash ratio as 2.79. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) showed a positive weekly performance of 3.69%.
On May 15, Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results of the first quarter ended March 31, 2014. Revenue for the first quarter of 2014 increased 9.0% to approximately $13.2 million compared to $12.1 million for the first quarter of 2013. The increase is mainly attributable to the increase in sales volume of other Aoxing products and Weinan products and the addition of 4 new products at Shaanxi Weinan. The increase in sales volume is mainly due to the positive image spread by the hospital using our products. Our sales prices didn’t change much in the first quarter of 2014. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) net profit margin is -10.40% and weekly performance is 2.22%. On last trading day company shares ended up $1.38. Analysts mean target price for the company is $7.00. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) distance from 50-day simple moving average (SMA50) is -20.76%.